About Curative Ventures
Curative Ventures is a venture capital firm founded in 2010. It is primarily based out of Dallas, United States. As of Apr 2020, Curative Ventures has invested in 5 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across Life Sciences and Healthcare sectors. Most recently it participated in the $***** Series B round of iTeos Therapeutics Overall, Curative Ventures portfolio has seen 2 IPOs and 3 acquisitions including key companies like iTeos Therapeutics, Peloton Therapeutics and Instil Bio. A lot of funds co-invest with Curative Ventures, with names like 6 Dimensions Capital sharing a substantial percentage of its portfolio. Curative Ventures has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B & Series E
Portfolio IPOs
Portfolio Acquisitions
Curative Ventures' List of All Investments
Curative Ventures has a portfolio of 5 companies. Their most notable investmentis in TCR2 TherapeuticsTheir portfolio spans across United States, Belgium and United Kingdom. They have invested in Life Sciences, Healthcare, across Series B, Series E stages. Here is the list of all investments by Curative Ventures:
iTeos Therapeutics is developing anti-cancer agents for treating cancer. The company pipeline products address immuno-oncology by targeting immuno-metabolism and immunosuppressive cells of the tumor micro-environment. The flagship product Adenosine A2A receptor antagonist is in early phase clinical trials and TIGIT immune checkpoint blocking antibody.
Key facts about iTeos Therapeutics
- Founded Year: 2011
- Location: Cambridge (United States)
- Annual Revenue: €32.5M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $204M
- Employee Count: 38 as on Mar 31, 2026
- Investors: HTIF, Boxer Capital and 19 Others
- Latest Funding Round: Series B, Apr 01, 2020, $*****
- Highlight: Acquired
Peloton Therapeutics has developed small molecule therapies for life-threatening diseases. Its lead candidate, PT2385, is a HIF-2α inhibitor (completed phase 2 clinical trials) for the treatment of advanced or metastatic clear cell renal cell carcinoma (ccRCC). It is also developing PT2385 in combination with immuno-oncology drugs for the treatment of ccRCC, and for the treatment of solid tumors. The company is a subsidiary of Merck & Co.
Key facts about Peloton Therapeutics
- Founded Year: 2010
- Location: Dallas (United States)
- Stage: Acquired
- Total Funding till date: $243M
- Employee Count: 62 as on Dec 31, 2022
- Investors: BVF Partners, RA Capital Management and 14 Others
- Latest Funding Round: Series E, Feb 20, 2019, $*****
- Highlight: Acquired
3. Instil Bio
Key facts about Instil Bio
- Founded Year: 2018
- Location: Manchester (United Kingdom)
- Annual Revenue: £2.02K as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $371M
- Employee Count: 56 as on Mar 31, 2026
- Investors: Vivo Capital, Curative Ventures and 1 Other
- Latest Funding Round: Series D, Dec 30, 2020, $*****
- Highlight: Public
TCR2 Therapeutics is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company has developed a unique proprietary TRuC platform based on T cell receptor fusion constructs. The company's claims that its TRuC variants can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit the killing of cancer cells. In preclinical studies, the company has demonstrated the activity of TRuC variants against both hematological and solid tumors.
Key facts about TCR2 Therapeutics
- Founded Year: 2015
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $170M
- Employee Count: 58 as on Dec 31, 2021
- Investors: ArrowMark Partners, F2 Ventures and 15 Others
- Latest Funding Round: Series B, Mar 21, 2018, $*****
- Highlight: Public
Urban regeneration development company creating sustainable value through innovative real estate projects. They are a development company specializing in large-scale urban regeneration projects, focusing on creating human-centric smart districts. Their integrated approach combines multidisciplinary expertise with innovation and sustainability, guiding projects from strategic conception to operational management. They offer solutions for urban transformation, integrating technology, sustainability, and human well-being to create intelligent, connected, and sustainable spaces. Their business units encompass development, project management, management company services, and experience design. They focus on real estate development, asset management, and creating innovative solutions for the future of work and living. They adopt ESG principles to ensure a positive and lasting impact on territories, communities, and the environment.
Key facts about CoStim Pharmaceuticals
- Founded Year: 2012
- Location: Boston (United States)
- Stage: Acquired
- Total Funding till date: $10M
- Employee Count: 11 - 50 as on Jul 01, 2024
- Investors: Curative Ventures, Partners Health Care Innovation and 2 Others
- Latest Funding Round: Series A, Apr 10, 2013, $*****
- Highlight: Acquired
Curative Ventures' Year-on-Year Investment Trends
Its most recent first time investment was in Peloton Therapeutics and most recent follow-on round was in iTeos Therapeutics.Curative Ventures' Investments by Stage
Curative Ventures has made 2 investments in Series B stage with an average round size of $100M and 1 investment in Series E stage with an average round size of $150M.Stage of entry | No. of Investments |
|---|---|
Series B | 2 |
Series E | 1 |
Note: We have considered here, only first round of investments
Curative Ventures' Investments by Sector
Curative Ventures has a portfolio focused on Life Sciences. Notably, it has invested in 3 Enterprise (B2B) companies and 3 Tech companies.Curative Ventures' Investments by Geography
Curative Ventures has made most investments in United States (3), followed by Belgium where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 3 |
Belgium | 1 |
Note: We have considered here, only first round of investments
Curative Ventures' recent investments
Curative Ventures has not made any investment in 2026 so far.Here are the most recent investments by Curative Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 01, 2020 | United States | Series B | 1934 | [+10] | |
Feb 20, 2019 | United States | Series E | 6765 | [+11] | |
Jun 20, 2018 | United States | Series B | 2937 | [+6] | |
Mar 21, 2018 | United States | Series B | 5381 | [+12] |
IPOs and Publicly Listed companies in Curative Ventures' Portfolio
2 of Curative Ventures' portfolio companies have become public. Instil Bio got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Mar 2021 at marketcap of $2.52B.Here are Curative Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 19, 2021 | - | - | 8800 | |
- | Mar 21, 2018 | Series B | 3690 |
Acquired companies in Curative Ventures' Portfolio
3 companies from Curative Ventures' portfolio have been acquired. The most recent acquisition was iTeos Therapeutics in Jul 2025 by Concentra Biosciences for $*****.Here are Curative Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 21, 2025 | Jun 20, 2018 | Series B | 9775 | |
Jan 11, 2024 | - | - | 2982 | |
May 21, 2019 | Feb 20, 2019 | Series E | 3791 |
Team profile of Curative Ventures
Curative Ventures has a team of 1 member located in United States. Curative Ventures' team does not sit on the board of any company as of now.Co-investors of Curative Ventures
Over the past 8 years, 45 investors have co-invested in Curative Ventures's portfolio companies. This includes only funds.
- Invested before Curative Ventures: SRIW, Vives Fund and 13 others have invested in rounds before Curative Ventures. There is 1 company where SRIW has invested before Curative Ventures and 1 company where Vives Fund has invested before Curative Ventures.
- Top Co-investors of Curative Ventures: 25 investors entered a company along with Curative Ventures. These include investors like 6 Dimensions Capital (2 companies).
- Invested after Curative Ventures: A total of 5 investors have invested in Curative Ventures's portfolio after their investments. Top Investors include RA Capital Management (1 company), Boxer Capital (1 company) and RTW Investments (1 company).
Recent News related to Curative Ventures
•
iTeos Therapeutics Raises $125M in Series B2 FundingFinSMEs•Apr 01, 2020•iTeos Therapeutics, RA Capital Management, Boxer Capital, Janus Henderson Investors and 14 others
•
Merck to acquire Peloton Therapeutics for $1.05 billionPoandpo•May 19, 2019•Peloton Therapeutics, Merck, Covington & Burling, Wilson Sonsini Goodrich & Rosati and 15 others
•
Peloton Therapeutics Secures $150 Million in Series E FinancingBusiness Wire•Feb 20, 2019•Peloton Therapeutics, Orbimed, Vida Ventures, The Column Group and 14 others
•
Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the ClinicLabiotech•Jun 20, 2018•iTeos Therapeutics, MPM BioImpact, HBM Partners, 6 Dimensions Capital and 5 others
•
ITeos raises $75M to trial immuno-oncology drugsFierce Biotech•Jun 20, 2018•iTeos Therapeutics, HBM Partners, 6 Dimensions Capital, Curative Ventures and 4 others
•
•
TCR2 Therapeutics’ $125 Million Series B FinancingGlobal Legal Chronicle•Mar 26, 2018•TCR2 Therapeutics, 6 Dimensions Capital, Curative Ventures, Redmile Group and 13 others
•
Venture Capital Access Online | Venture Capital NewsVCA Online•Mar 21, 2018•TCR2 Therapeutics, 6 Dimensions Capital, Curative Ventures, Redmile Group and 11 others
